Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HyperfineHYPR -2.92%79 FCF Margin % is -186.94% as of Jun. 2026. GuruFocus rates HYPR with a GF Score™ of 79/100 and a GF Value™ of $1.27 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Hyperfine ranks worse than 88.45% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hyperfine's Free Cash Flow for the
three
months ended in Jun. 2026 was $-7.30 Mil. Hyperfine's Revenue for the
three
months ended in Jun. 2026 was $3.90 Mil. Therefore, Hyperfine's FCF Margin % for the quarter that ended in Jun. 2026 was -186.94%.
The historical data trend for Hyperfine's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HYPR vs RPID, ZOMDF, SERA: FCF Margin % Comparison
For the Medical Devices subindustry, Hyperfine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyperfine FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hyperfine's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Hyperfine's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyperfine (HYPR) has a FCF Margin % of -186.94% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hyperfine and its competitors. According to the industry distribution chart, Hyperfine ranks #720 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 88.5%.
Is Hyperfine's FCF Margin % too high?
Hyperfine's current FCF Margin % is -186.94%. Based on the distribution chart, Hyperfine ranks #720 out of 814 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Hyperfine has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hyperfine's FCF Margin % compare to RPID and ZOMDF?
According to the Medical Devices & Instruments industry distribution chart, Hyperfine ranks #720 out of 814 companies for FCF Margin %. This places Hyperfine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hyperfine and its competitors. Hyperfine's current FCF Margin % is -186.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyperfine stock overvalued right now?
Based on GuruFocus' analysis, Hyperfine (HYPR) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.27, compared to a current price of $0.95 — trading 25.3% below its estimated fair value. The current FCF Margin % is -186.94%. Hyperfine's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hyperfine (HYPR), the current FCF Margin % is -186.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyperfine (HYPR) Overvalued in 2026?
Based on GuruFocus' analysis, Hyperfine stock appears to be undervalued.
The current stock price of $0.95 is trading 25.3% below its estimated GF Value™ of $1.27.
GuruFocus considers Hyperfine to be Modestly Undervalued.
Key valuation signals for HYPR:
FCF Margin %: -186.94%
GF Value™: $1.27 vs. price of $0.95 (25.3% below fair value)
No single metric tells the full story. See the HYPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
79GF Score
Get the complete analysis for HYPR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYPR has been successfully added to your 
